12ea8f7c7c84d737…

{
  "id": "NCT00104013",
  "type": "Study",
  "data": {
    "briefSummary": "The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).",
    "completionDate": "2007-11",
    "conditions": [
      "Alzheimer Disease"
    ],
    "enrollmentCount": 1455,
    "enrollmentType": "ACTUAL",
    "nctId": "NCT00104013",
    "phase": "PHASE3",
    "sponsorId": "sanofi",
    "startDate": "2003-11",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",
    "url": "https://clinicaltrials.gov/study/NCT00104013"
  }
}